Antibiotice continues to develop several strategic projects for the pharmaceutical industry through a 67 million euros in funding granted by Banca Transilvania. The investment supports the implementation of two key projects aimed at strengthening the company’s production and innovation capabilities.

”Production, packaging, storage capacity for sterile products, solutions and topicals” – is one of the most important investment projects developed by Antibiotice Iași in recent years. By this investment, the company strengthens its strategic position in the topicals and sterile solutions segments, both domestically and internationally, by diversifying the essential medicine portfolio used in hospitals.

The project has started with funding from the European Investment Bank in Romania through the InvestEU program and also benefits from non-reimbursable funds granted by the Ministry of Finance.

INOVA Research & Development Center+ and the new production site for critical medicines represents a strategic investment, with a major impact on the health security of Romania and Europe. The project contributes to strengthening Romania’s capacity to produce critical medicines locally, reducing dependence on external supply chains and supporting the European Union’s objectives regarding strategic autonomy in the field of health.

This investment strengthens the Antibiotice’s long term growth prospects by developing innovation capabilities, expanding its product portfolio and increasing competitiveness on international markets. The project also includes a non-reimbursable funding component provided by the Ministry of Investments and European Projects, through the STEP (Strategic Technologies for Europe Platform) program.

„This financing strengthens the capacity of Antibiotice Iași to accelerate strategic investments and support long-term growth objectives, both in the Romanian market and internationally. Our partnership with the Banca Transilvania reflects confidence in our development direction and in the company’s potential to generate sustainable value for the healthcare system, partners and shareholders” declared Ioan Nani, General Director of Antibiotice SA.